CAS 518048-05-0: Raltegravir
Formula:C20H21FN6O5
InChI:InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
InChI key:InChIKey=CZFFBEXEKNGXKS-UHFFFAOYSA-N
SMILES:C(NC(=O)C1=NN=C(C)O1)(C)(C)C2=NC(C(NCC3=CC=C(F)C=C3)=O)=C(O)C(=O)N2C
Synonyms:- 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-
- 5-Hydroxy-2-[1-[[(5-Methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]-1-methylethyl]-N-(4-fluorobenzyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide
- N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
- N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide
- Raltegravir
Sort by
Found 10 products.
Raltegravir - Bio-X ™
CAS:Raltegravir is an antiretroviral agent used for the treatment of HIV infections in conjunction with other antiretrovirals. It inhibits the activity of HIV-1 integrase, which impedes the insertion of HIV-1 DNA into the host cell genome. Raltegravir also inhibits resistant mutants of HIV-1 that are associated with disease activity and progression. Raltegravir is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.Formula:C20H21FN6O5Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:444.42 g/molRaltegravir
CAS:Formula:C20H21FN6O5Purity:≥ 99.0%Color and Shape:White to off-white crystalline powderMolecular weight:444.42Raltegravir
CAS:Controlled ProductApplications Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN. References Hare, S., et al.: Proc. Natl. Acad. Sci. U. S. A., 107, 20057 (2010); Hicks, C., et al.: Clin. Infect. Dis., 48, 931 (2009); Moss, D., et al.: Antimicrob. Agents Chemother., 56, 3020 (2012); Hare, S., et al.: Mol. Pharmacol., 80, 565 (2011)Formula:C20H21FN6O5Color and Shape:NeatMolecular weight:444.42Raltegravir
CAS:Raltegravir is an antiretroviral agent, which is a synthetic integrase inhibitor sourced from pharmaceutical research. Its mode of action involves the inhibition of the HIV-1 integrase enzyme, which is essential for the viral replication process. By blocking the strand transfer step of the integration of viral DNA into the host cell genome, Raltegravir prevents the proliferation of the virus within the host. The primary use of Raltegravir is in the treatment of HIV-1 infection in combination with other antiretroviral agents. It is an integral part of highly active antiretroviral therapy (HAART) and is crucial for the management of patients who require a potent antiretroviral response, particularly in cases where resistance to other treatments may be a concern. Raltegravir is also utilized in both initial treatment settings and for patients who have experienced therapeutic failures with other regimens. Its efficacy and safety profile make it a critical component in the ongoing battle against HIV/AIDS, offering hope for improved patient outcomes and quality of life.Formula:C20H21FN6O5Purity:Min. 98 Area-%Color and Shape:White Off-White PowderMolecular weight:444.42 g/molRaltegravir
CAS:Raltegravir (MK-0518) is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIVFormula:C20H21FN6O5Purity:100% - 99.86%Color and Shape:SolidMolecular weight:444.42
